Nowe dodatki funkcjonalne do żywności i suplementów diety - karetonoidy morskie

• Autorzy: Czerwonka M. , Waszkiewicz-Robak B.

Warianty tytułu

EN

Anew functional ingredients - sea carotenoids

• Języki publikacji: PL

Abstrakty

PL

Rozwijający się rynek żywności funkcjonalnej i suplementów diety zmusza producentów do poszukiwania nowych substancji, które spełnią wymagania konsumentów w zakresie pozytywnego oddziałania na organizm i bezpieczeństwa stosowania. Karotenoidy z alg morskich, astaksantyna ifukoksantyna, są nowością na rynku światowym. Dostarczone do organizmu człowieka mogą pełnić bardzo ważną rolę w prewencji i leczeniu wielu chorób cywilizacyjnych. Oba związki są silnymi przećiwutleniaczami, a dzięki tym właściwościom wykazują działanie m. in.: kardioprotekcyjne, przeciwzapalne, przeciwnowotworowe, wspomagające redukcję masy ciała, regulujące poziom glukozy we krwi.

EN

The increasing market of functional food and supplements of the diet is forcing the producers searching the new substances, which consumers would appreciate for positive influence of the body and safety use. Sea algae carotenoids, astaxanthin and fucoxanthin, are the novelty on the world market, in the human body they are able to play very important role in the prevention and the treatment of many civilization diseases. Both are a strong antioxidants, thanks to this properties, they had an effect: cardioprotective, anti-inflammatory, anticancerogenic, weight management, regulating the level of glucose in blood.

• Wydawca: Wyższa Szkoła Menadżerska
• Czasopismo: Postępy Techniki Przetwórstwa Spożywczego
• Rocznik: 2008
• Tom: nr 2
• Strony: 70--74
• Opis fizyczny: Bibliogr. 51 poz., rys.

Twórcy

autor

Czerwonka M.

autor

Waszkiewicz-Robak B.

• SGGW w Warszawie, Wydział Nauk o Żywieniu Człowieka i Komsumpcji

Bibliografia

• [1] Anderson M.: Method of Inhibiting 5-a Reductase witki Astaxanthin to Prevent and Treat Begnign Prostatę Hy-I perplasia (BPH) and Prostate Cancer in Human Males, US 2001, Patent #6277417.
• [2] Aoi W., Naito Y., Sakuma K., Kuchide M, Tokuda H,[ Maoka T., Toyokuni S., Oka S., Yasuhara M, Yoshikawa I T.: Astaxanthin limits exercise-induced skeletal and car-1 diac muscle damage in mice, Antioxid Redox Signal.,B 2003,(5)1, 139-144.
• [3] Asai A., Sugawara T., Ogo H., Nagao A.: Biotransfor-1 mation of fucoxanthinol into amarouciaxanthin A in I mice and HepG2 cells: formation and cytotoxicity of fu-coxanthin metabolites, Drug Metab Dispos, 2004,32(2), I 205-211.
• [4] Bennedsen M.: Treatment of H. pylori infected mice I with antioxidant astaxanthin reduces gastric inflamma-1 tion, bacterial load and modulates cytokine release by I splenocytes. Immunol Lett, 1999, 70(3), 185-189.
• [5] Capelli B.: Astaksantyna, Naturalna Astaksantyna I - Królowa Karotenoidów, 2007, http://kenayag.com.pl/1 dok/astaksantyna.pdf.
• [6] Das S.K., Hashimoto T., Kanazawa K.: Growth inhibi- I tion of human hepatic carcinoma HepG2 cells by fuco- I xanthin is associated with down-regulation of cyclin D., Biochim Biophys Acta, 2008, 1780(4), 743-749.
• [7] Dominguez-Bocanegra A.R. Guerrero Legarretal., Martinez Jeronimo F., Tomasini Campocosio A.: Influence of environmental and nutritional factors in the produc-tion of astaxanthin from Haematococcus pluvialis, Bio-resour Technol., 2004, 92(2), 209-214.
• [8] Guerin M., Huntley M.E., Olaizola M.: Haematococcus astaxanthin: applications for human health and nutrition, Trends Biotechnol., 2003, 21(5), 210-216.
• [9] Gross G.J., Hazen S.L., Lockwood S.F.: Seven day orał supplementation with Cardax (disodium disuccinate astaxanthin) provides significant cardioprotection and reduces oxidative stress in rats, Mol Celi Biochem., 2006, 283(1-2), 23-30.
• [10] Gross G.J., Lockwood S.F.: Cardioprotection and my-ocardial salvage by a disodium disuccinate astaxanthin derivative (Cardax), Life Sci., 2004, 75(2), 215-224.
• [11] Gross G.J., Lockwood S.F.: Acute and chronić admini- stration of disodium disuccinate astaxanthin (Cardax) produces marked cardioprotection in dog hearts, Mol Celi Biochem., 2005, 272(1-2), 221-227.
• [12] Hosokawa M., Kudo M., Maeda H., Kohno H., Tanaka T., Miyashita K.: Fucoxanthin induces apoptosis and enhances the antiproliferative effect of the PPARgamma ligand, troglitazone, on colon cancer cells, Biochim Biophys Acta, 2004, 1675(1-3), 113-119.
• [13] Hussein G., Goto H., Oda S., Sankawa U., Matsumoto K, Watanabe H.: Antihypertensive potential and mecha-nism of action of astaxanthin: III. Antioxidant and histo-pathological effects in spontaneously hypertensive rats, Biol Pharm Buli., 2006, 29(4), 684-688.
• [14] Hussein G., Nakagawa T., Goto H., Shimada Y., Matsu-moto K., Sankawa U., Watanabe H.: Astaxanthin ame-liorates features of metabolic syndrome in SHR/NDmcr-cp, Life Sci., 2007, 80(6), 522-529.
• [15] Hussein G., Nakamura M., Zhao Q., Iguchi T., Goto H., Sankawa U., Watanabe H.: Antihypertensive and neu-roprotective effects of astaxanthin in experimental ani-mals, Biol Pharm Buli., 2005, 28(1), 47-52.
• [16] Ikeda K., Kitamura A., Machida H., Watanabe M., Negi-shi H., Hiraoka J., Nakano T.: Effect of Undaria pinna-tifida (Wakame) on the development of cerebrovascular diseases in stroke-prone spontaneously hypertensive rats, Clin Exp Pharmacol Physiol., 2003, 30(1-2), 44-48.
• [17] Ikeuchi M., Koyama T., Takahashi J., Yazawa K.: Effects of astaxanthin supplementation on exercise-indu-ced fatigue in mice, Biol Pharm Buli, 2006, 29(10), 2106-2110.
• [18] Kenji S., Kazuhiro O, Takuya N., Yasuhiro S., Shinki C, Kazuhiko Y: Effect of astaxanthin on accommoda-tion and asthenopia - Efficacy - identification study in healthy volunteers, Journal of Clinical Therapeutics and Medicines, 2005, 21(6), 637-650.
• [19] Kotake-Nara E., Kushiro M., Zhang H., Sugawara T, Miyashita K., Nagao A.: Carotenoids affect proliferation of human prostate cancer cells, J Nutr., 200, 131(12), 3303-3306.
• [20] Lee S.J., Bai S.K., Lee K.S., Namkoong S., Na H.J., Ha K.S., Han J.A., Yim S.V., Chang K., Kwon Y.G., Lee S.K., Kim Y.M.: Astaxanthin inhibits nitric oxide pro-duction and inflammatory gene expression by suppres-sing I(kappa)B kinase-dependent NF-kappaB activation, Mol Cells., 2003, 16(1), 97-105.
• [21] Lockwood S.E, Gross G.J.: Disodium disuccinate astaxan-thin (Cardax): antioxidant and antiinflammatory cardiopro-tection, Cardiovasc Drug Rev., 2005, 23(3), 199-216.
• [22] Lockwood S.E, Jackson H.L., Gross G.J.: Retrometa-bolic syntheses of astaxanthin (3,3'-dihydroxy-beta,be-ta-carotene-4,4'-dione) conjugates: a novel approach to orał and parenteral cardio-protection, Cardiovasc Hema-tol Agents Med Chem., 2006, 4(4), 335-349.
• [23] Lockwood S.F., Penn M.S., Hazen S.L., Bikadi Z., Zsi-la E: The effects of orał Cardax (disodium disuccinate astaxanthin) on multiple independent oxidative stress markers in a mouse peritoneal inflammation model: influence on 5-lipoxygenase in vitro and in vivo, Life Sci., 2006, 79(2), 162-174.
• [24] Lyons N.M., 0'Brien N.M.: Modulatory effects of an algal extract containing astaxanthin on UVA-irradiated cells in culture, J Dermatol Sci., 2002, 30(1), 73-84.
• [25] Maeda H., Hosokawa M., Sashima T, Funayama K., Miyashita K.: Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues, Biochem Biophys Res Commun, 2005, 332(2), 392-397.
• [26] Maeda H., Hosokawa M., Sashima T, Funayama K, Miyashita K.: Effect of medium-chain triacylglycerols on anti-obesity effect of fucoxanthin, 2007, 56(12), 615-621.
• [27] MaedaH., HosokawaM., SashimaT, Miyashita K: Die-tary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decreases blood glucose in obese/diabetic KK-Ay mice, J Agric Food Chem., 2007, 55(19), 7701-7706.
• [28] Maeda H., Tsukui T, Sashima T, Hosokawa M., Miyashita K: Seaweed carotenoid, fucoxanthin, as a multi-functional nutrient, Asia Pac J Clin Nutr,2008, 17(Suppl 1), 196-199.
• [29] Mera Pharmaceuticals: Haematococcus pluvialis and astaxanthin safety for human consumption, Technical Report 1999, http://www.astafactor.com/techreports/ tr3005-001.htm.
• [30] Miyashita K, Hosokawa M.: Beneficial Health Effects of Seaweed Carotenoid, Fucoxanthin, [in] Barrow C, Shahidi F., Marine nutraceuticals and functional foods, Published by CRC Press 2007.
• [31] Nagaki Y, Hayasaka S., Yamada T, Hayasaka T, Sana-da M.: Effects of astaxanthin on accommodation, criti-cal flicker fusion, and pattern visual evoked potential in visual display terminal workers, Journal of Traditional Medicines, 2002, 19(5), 170-173.
• [32] Nakamura A., Isobe R., Yasuhiro O., Abematsu Y, Da-isuke N., Honma C, Sakurai S.: Changes in visual func-tion following peroral astaxanthin, Japanese Journal of Clinical Ophthalmology, 2004, 58(6), 1051-1054.
• [33] Nagaki Y, Mihara M., Hiroki T, Shigeaki O.: The supplementation effect of Astaxanthin on Accommodation and Astenopia, 2006, 22(1), 41-54.
• [34] Nagaki Y, Mihata M., Takahashi J., Kitamura A., Horita Y: The Effect of Astaxanthin on Retinal Capillary Blood Flow in Normal Volunteers, Journal of Clinical Therapeutics & Medicines, 2005, 21(5), 537-542.
• [35] Nishikawa Y, Mineneka Y, Ichimura M., Tatsumi K, Nadamoto T.: Effects of astaxanthin and vitamin C on the prevention of gastric ulcerations in stressed rats, Journal of nutritional science and vitaminology, 2005, 51(3), 135-141.
• [36] Nishino H., Tsushima M., Matsuno T, Tanaka Y, Oku-zumi J., Murakoshi M., Satomi Y, Takayasu J., Tokuda H., Nishino A.: Anti-neoplastic effect of halocynthia-xanthin, a metabolite of fucoxanthin, Anticancer Drugs, 1992, 3(5), 493-497.
• [37] Nitta T, Ogami K, Shiratori K., Shinmei Y, Chin S., Yoshida K.: Effects of Astaxanthin on Accommodation and Asthenopia-Dose Finding Study in Healthy Volunte-ers, Journal of Clinical Therapeutics & Medicines, 2005, 21(5), 543-556.
• [38] CConnor I., 0'Brien N: Modulation of UVA light-in-duced oxidative stress by beta-carotene, lutein and asta-xanthin in cultured fibroblasts, J Dermatol Sci., 1998, 16(3), 226-230.
• [39] Ohgami K, Shiratori K, Kotake S., Nishida T, Mizuki N.: Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo, Invest Ophthalmol Vis Sci., 2003, 44(6), 2694-2701.
• [40] Pashkow F.J., Watumull D.G., Campbell CL.: Astaxan-thin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease, Am J Cardiol., 2008, 101(10A), 58D-68D.
• [41] Sachindra N.M., Sato E., Maeda H., Hosokawa M., Ni-wano Y., Kohno M., Miyashit K.: Radical scavenging and singlet oxygen ąuenching activity of marine carotenoid fucoxanthin and its metabolites, J Agric Food Chem, 207, 55(21), 8516-8522.
• [42] Santocono M., Zurria M., Berrettini M., Fedeli D., Falcioni G.: Influence of astaxanthin, zeaxanthin and lute-in on DNA damage and repair in UVA-irradiated cells, J Photochem Photobiol B., 2006, 85(3), 205-215.
• [43] Shiratori K., Ohgami K., Ilieva I., Jin X.H., Koyama Y, Miyashita K., Yoshida K., Kase S., Ohno S.: Effects of fucoxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo, Exp Eye Res., 205, 81(4), 422-428.
• [44] Seki T., Sueki H., Kono H., Kaoru S., Eiji Y: Effects of astaxanthin from Haematococcus pluvialis on human skin, Patch testing Skin repeated application test Effect on wrinkle reduction, Fragr J, 2001, 29(12), 98-103.
• [45] Takimoto T., Takahashi K., Akiba Y: Effect of dietary supplementation of astaxanthin by Phaffia rhodozyma on lipid peroxidation, drug metabolism and some immunological variables in male broiler chicks fed on diets with or without oxidised fat. Br Poult Sci., 2007, 48(1), 90-97.
• [46] Tanaka T., Kawamori T., Ohnishi M., Makita H., Mori H., Satoh K., Hara A.: Suppression of azomethane-induced rat colon carcinogenesis by dietary administration of naturally occurring xanthophylls astaxanthin and can-thaxanthin during the postinitiation phase, Carcinogenesis, 1995, 16, 2957-2963.
• [47] Tanaka T., Morishita Y, Suzui M., Kojima T., Okumura A., Mori H.: Chemoprevention of mouse urinary bladder carcinogenesis by the naturally occurring carotenoid astaxanthin, Carcinogenesis, 1994, 15, 15-19.
• [48] Tso M.O.M., Lam T.T.: Method of Retarding and Ame-liorating Central Nervous System and Eye Damage. U.S. 1996, Patent #5527533.
• [49] Wang X., Willen R., Wadstróm T.: Astaxanthin-rich al-gal meal and vitamin C inhibit Helicobacter pylori infection in BALB/cA mice, Antimicrob Agents Chemother., 2000, 44(9), 2452-2457.
• [50] Victor V.M., Rocha M.: Targeting antioxidants to mito-chondria: a potential new therapeutic strategy for cardio-vascular diseases, Curr Pharm Des., 2007, 13(8), 845-863.
• [51 ] Yamashita E.: Cosmetic benefit of the supplement health food combined astaxanthin and tocotrienol on human skin, Food Style, 2002, 21 (6), 112-117.